THE INFORMATION CONTAINED WITHIN THIS
ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE
INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU)
NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"),
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
28th May 2021
DiscovOre plc
AQSE: ORE
(“DiscovOre” or
the “Company”)
DiscovOre plc
submits application to begin trading on the OTCQB & Corporate
Update
Particulars of the RIS
Announcement
- OTCQB Application
- Corporate Update
- Directors Statement
- OTCQB Application
Following the successful fundraise and intention to change the
Company’s investment strategy, DiscovOre plc has submitted its
application to the OTC Markets Group Inc., that upon completion
will allow tradability in, arguably, the worlds deepest and most
liquid capital market, the United States
of America.
As the Company works to become the first Investment Issuer in
the U.K. offering exposure to medical psychedelic opportunities,
the Company views this as an important step as it prepares to
increase market visbility and capture a wider audience of market
participants.
The OTCQB is a strong market for DiscovOre plc to have its
shares available and conditional on both the requisite legal work
and the consent of the Company’s shareholders we will join a host
of companies currently operating in the medical psychedelic
industry including;
- Mind Medicine (MindMed) Inc. (OTCQB: MMEDF) Market
Capitalisation: ~US$1bn
- Compass Pathways (CMPS) Market Capitalisation: ~US$1bn
- Cybin Inc (OTC: CLXPF) Market Capitalisation: ~US$207,000,000
- Numinus Wellnes Inc. (OTC: LKYSF) Market Capitalisation:
~US$152,755,898
- Corporate Update
The Company is actively working with its Corporate Advisor &
Legal Counsel to advance this new investment strategy and expect to
have an update in the following weeks that is likely to be in
conjunction with the Company posting a circular to convene a
General Meeting, including amongst proposals, the new investment
strategy.
The Company recently incorporated a subsidiary, named Oscillate
Limited which will represent the proposed name change (“Oscillate
plc”) that will be subject to the consent of the shareholders and
will better reflect the proposed direction of the Company, in
addition to a new corporate branding exercise.
- Director Statement
“The completion of the £3,500,000 strategic financing at the
end of April marked a significant moment for the Company. DiscovOre
plc is now, exceptionally well financed and the Company is
advancing with purpose as we continue to progress with all the
requisite legal-work required to enable the business to lawfully
invest in this industry.
As recent as last week the BBC
broadcast a documentary that amongst many fascinating insights drew
acute attention to the revolution we are entering in healthcare and
the integral role alternative treatments such as medical
psyechedelics play as the world look to improve the lives of many
suffering from mental healh conditions.
The application submitted to commence
trading on the OTCQB represents the intention the Company has in
ensuring that we create tradable conditions, domestic market access
for investors and to ensure that the Company is exposed to capital
market participants that have to date raised billions in capital in
this burgeoning industry.
I look forward to updating the market
with the company’s next stage of development in the near term.”
DiscovOre plc,
London, 28th May 2021
The Directors of the Company, who have
issued this RIS announcement after due and careful enquiry, accept
responsibility for its content.
Enquiries
Company:
Burns Singh Tennent-Bhohi (Director)
Conrad Windham (Director)
info@discovoreplc.com
Direct Office Line: +44 (0) 20 3778 0755
Corporate Adviser:
Peterhouse Capital Limited
Guy Miller & Mark Anwyl
Telephone: +44 (0) 20 7220 9796